Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Granisetron in sepsis or septic shock
NCT03924518Phase 2Completed
- Sponsor
- Southern Medical University Zhujiang Hospital
- Start
- Apr 2019
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of granisetron in sepsis and septic shock, sponsored by Southern Medical University Zhujiang Hospital. Primary endpoint: All-Cause Mortality Rate at 28 days. Started Apr 2019; status: completed.
02
Drugs
granisetron
03
Conditions
sepsisseptic shock
Beyond the preview
Go deeper on NCT03924518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03924518.